Drug intelligence / Profile preview

GQ1009

Development stage: Preclinical
Lead developer: GeneQuantum Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GQ1009 is an investigational antibody-drug conjugate (ADC) developed by GeneQuantum Healthcare. It is engineered using the company's proprietary intelligent Ligase Dependent Conjugation (iLDC) technology, which is designed to enable site-specific conjugation for the production of highly homogeneous and stable ADCs. As of the current pipeline disclosures, the specific molecular target and the primary disease indications for GQ1009 remain undisclosed by the developer.

Beyond the preview

Go deeper on GQ1009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ1009.

Explore the full profile